Reimbursement

For your convenience, below are the NDC, HCPCS, ICD-9-CM and CPT reimbursement codes for Humate-P. This resource provides information from a complex and evolving medical coding system. The treating physician is solely responsible for diagnosis coding and determination of the appropriate ICD-9-CM codes that describe the patient's condition and are supported by the medical record. All codes listed in this guide are for informational purposes and are not an exhaustive list. The CPT, HCPCS, and ICD- 9-CM codes provided are based on AMA or CMS guidelines. The billing party is solely responsible for coding of services (e,g., CPT Coding), Because government and other third-party payor coding requirements change periodically, please verify current coding requirements directly with the payor being billed.

Coding Information for Humate-P

Our Reimbursement Resource Center provides additional information on insurance matters, coverage trends, patient assistance, and more.

Or, call CSL Behring's Reimbursement Answerline (1-800-676-4266) for assistance with individual case inquiries on a variety of reimbursement services, including:

claim processing reviews
appeals
insurance investigations into product coverage
prior approvals for therapies authorization

You can also write to:
CSL Behring
1020 First Avenue
P.O. Box 61501
King of Prussia, PA 19406-0901
Patient Assistance Program

Important Safety Information

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided here is primarily intended for use by physicians and other healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.